The Activation of PI3K/AKT/mTOR Signaling Pathway in Response to Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer Cells
نویسندگان
چکیده
Objective: Despite advances in treatment approaches, metastatic castration-resistant prostate cancer (mCRPC) remains a clinical challenge to treat. Cabazitaxel (Cab), third-line chemotherapy option for mCRPC, exhibits limited efficiency due the activation of different signaling pathways associated with drug resistance. The PI3K/AKT/mTOR has led mCRPC progression, and long-term acquired Cab However, we aimed assess association apoptotic cells present study. Materials Methods: Cell viability, cell death, morphological analysis, pathway by PI3K/MAPK dual assay, mRNA miRNA expression analysis immunofluorescence staining were performed Cabtreated PC3 cells. Results: caused significant reduction viability triggered death at 1 5 nM 72 h. significantly induced activation, increased activated protein levels AKT mTOR cells, despite its effect. Furthermore, expressions miR-205 miR-579, targeted miRNAs, upregulated after treatment. Our findings have shown that PI3K/ AKT/mTOR is effect Conclusion: Although further studies are required investigate molecular mechanisms accompanying response detail, as an alteration related drug, may play role resistance suggesting combined therapy inhibitors improve therapeutic efficiency.
منابع مشابه
Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel
متن کامل
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations
Cabazitaxel is an effective chemotherapeutic agent used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel. With the advent of new antiandrogen therapies, immune-based treatments, and radioactive-targeted therapy, there are now multiple effective and approved agents for this disease state. The optimal sequencing of these agents is unclear as ther...
متن کاملComplete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel
Dear Editor, About 20-40% of patients who undergo primary therapy for early-stage prostate cancer, experience biochemical relapse of which 30-70% develop metastatic disease within 10 years1 and the majority will become resistant to castration (CRPC). Since 2004, docetaxel has been the first-line cytotoxic treatment in treating metastatic CRPC. However, many mCRPC patients eventually become resi...
متن کاملCabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
Until recently, patients with castration-resistant prostate cancer (CRPC) had limited therapeutic options once they became refractory to docetaxel chemotherapy, and no treatments improved survival. This changed in June 2010 when the Food and Drug Administration (FDA) approved cabazitaxel as a new option for patients with CRPC whose disease progresses during or after docetaxel treatment. For mos...
متن کاملCabazitaxel in the Management of Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel-based Chemotherapy
Docetaxel is the guideline-recommended first-line chemotherapy in men with castration-resistant prostate cancer (CRPC). Despite its proven survival benefit, however, all patients will progress after a mean interval of six to eight months. Recently, the FDA approved cabazitaxel and abiraterone acetate as effective second-line treatment options in this clinical scenario. By comparison with mitoxa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European journal of biology
سال: 2021
ISSN: ['2618-6144']
DOI: https://doi.org/10.26650/eurjbiol.2021.1018938